Innovation Antibodies

Organizations develop immune-system-like responses that automatically attack and neutralize new ideas, regardless of their merit. The antibodies take specific forms: 'We tried that before' (history kill), 'That's not how we do things here' (culture kill), 'Where's the business case?' (premature ROI demand), 'Legal won't allow it' (authority kill), and 'Let's form a committee' (death by process). Each antibody sounds reasonable in isolation but collectively creates an environment where nothing new survives. The mechanism mirrors biological immune systems: past threats (failed projects) create memory cells (organizational trauma) that attack anything resembling the original pathogen (new ideas that pattern-match to old failures). Xerox PARC invented the GUI, ethernet, and laser printing but couldn't get any of them past Xerox's antibodies. The antibodies are especially potent when wielded by middle management, who often face asymmetric risk: a failed innovation hurts their career, while a blocked innovation is invisible.

When to use it

When proposing new initiatives in established organizations. When trying to understand why good ideas keep dying. When designing innovation processes. When evaluating whether an organization can actually execute a new strategy.

How it can help

Provides a taxonomy of specific blocking mechanisms so innovators can prepare countermeasures for each. Prevention at the organizational level requires creating 'immune-privileged sites'—skunkworks, innovation labs, or CEO-sponsored projects that bypass normal antibody responses. At the individual level, learn to inoculate your proposals against each antibody type: pre-answer 'we tried that before' by explaining what's different now, pre-answer 'where's the business case' with lightweight experiments rather than full projections. The most powerful structural fix: make middle managers' careers partially dependent on innovation throughput, not just operational stability.